Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Prescient Therapeutics Limited ( (AU:PTX) ) has shared an update.
Prescient Therapeutics Limited reported a decrease in interest revenue by 67.2% and a reduction in net loss by 11.1% for the year ending June 2025. The company recognized a significant R&D tax incentive rebate, reflecting its continued investment in research and development. Despite a decrease in corporate expenses, employment-related costs increased due to higher consulting fees and share-based payments. The company’s net assets decreased, primarily due to expenditures on R&D, corporate, and employment costs, impacting its financial position.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on the development of targeted therapies for cancer treatment. The company is engaged in research and development activities to advance its pipeline of innovative cancer drugs.
Average Trading Volume: 1,310,368
Technical Sentiment Signal: Sell
Current Market Cap: A$46.81M
Learn more about PTX stock on TipRanks’ Stock Analysis page.